It makes things in orbit, then drops them through the atmosphere on purpose. The factory floor just moved 250 miles up.
The wordmark of a company whose product line is, essentially, controlled falling. El Segundo, California.
In the South Australian outback, near a town most maps skip, a capsule the size of a beach ball comes down under a parachute. Inside is something that did not exist on Earth a few weeks earlier. This is Varda Space Industries on an ordinary Tuesday - and "ordinary" is exactly the point.
The capsule is the W-6, the sixth in a series, and it has just survived the part of spaceflight engineers usually spend their careers trying to avoid: the screaming, plasma-wrapped plunge back through the atmosphere. Varda did not survive reentry. Varda sold it.
Here is the inconvenient truth that started a company: a lot of useful chemistry works better without gravity in the room. Certain drug crystals grow more uniformly. Some materials separate more cleanly. On Earth, gravity pulls heavier components down, sets up convection currents, and generally makes a mess of processes that want to be still. Microgravity removes that variable entirely.
Scientists have known this since the Space Shuttle. The catch was never the science - it was the logistics. Getting an experiment to orbit was expensive and slow, and getting it back was harder still. For decades, "manufacturing in space" stayed a PowerPoint slide with a great future and no supply chain.
Then two things changed at once. SpaceX made launch cheap enough to treat orbit as a routine destination. And a generation of engineers who had built reusable rockets started asking what you could actually do up there once getting there stopped being the whole problem.
Will Bruey spent years at SpaceX as an engineer, working on the kind of hardware that has to work the first time because there is no second time. Delian Asparouhov, a partner at Founders Fund, had been turning over the idea of space manufacturing in public - partly in a viral thread that read more like a dare than a business plan. In January 2021 they put the two halves together.
The bet was specific and slightly absurd: build a small spacecraft that carries a tiny factory, run a manufacturing process while it orbits, then bring the finished goods home inside a reentry capsule that lands in a desert. Do it again. Then do it on a schedule. Turn the most exotic logistics problem in the solar system into something that looks, eventually, like a delivery route.
Varda's product line is the W-Series reentry capsule - an autonomous spacecraft that does three jobs in sequence. It hosts a processing payload in orbit. It runs that process in microgravity, untouched by human hands. Then it folds the results into a heat-shielded capsule and brings them down through the atmosphere to a soft landing under parachute.
A satellite bus carries the capsule to low Earth orbit and keeps it powered, pointed and alive while the work gets done.
Inside, pharmaceutical crystallization or materials processing runs autonomously in microgravity - no convection, no settling, no operator.
The capsule detaches and dives through the atmosphere behind a heat shield, then lands under parachute at a recovery range.
On the very first mission, W-1, Varda grew crystals of ritonavir - a decades-old HIV medication that is notoriously fussy about which crystal form it takes - and brought them home intact. It was the first time a commercial company manufactured a pharmaceutical in orbit and returned it. W-1 was also the first commercial spacecraft to land on a U.S. military test range, and it carried home a piece of NASA's experimental C-PICA heat-shield material as a bonus.
Somewhere along the way, Varda discovered it had built two products, not one. The capsule that protects drug crystals during a 25-times-the-speed-of-sound reentry is also a near-perfect hypersonic test platform. Strap a sensor to the outside, and a customer gets data on what actually happens in the plasma sheath of a returning vehicle. The U.S. Air Force noticed, and wrote a check for $48 million.
Bruey and Asparouhov found Varda in El Segundo with a seed round and a dare.
First commercial pharma manufactured in orbit (ritonavir) and first commercial landing on a U.S. military range.
Touchdown at Koonibba; the OSPREE payload captures reentry spectroscopy not seen in open scientific literature.
Another clean recovery at the Koonibba Test Range, tightening the flight cadence.
Led by Natural Capital and Shrug Capital; Varda crosses into unicorn territory.
First full mission lifecycle on Varda's own vertically integrated satellite bus.
Successful reentry validating autonomous navigation and advanced thermal protection - the second reentry of the year.
Skeptics of space startups have a fair question: is there revenue, or just runway? Varda's answer is a funding curve that has steepened with each landing. From a $9 million seed to a reported $250 million Series D, investors have priced the company as if routine reentry is a business, not a stunt.
*Series D figure reported; reported valuation near $1.58B. Bars scaled to the largest round.
The proof is not only financial. Each mission is a partnership stack: SpaceX provides the ride to orbit on Falcon 9 rideshare flights. Rocket Lab supplied the satellite buses for the early capsules before Varda built its own. NASA and the Air Force Research Laboratory fly payloads. And Southern Launch operates the Koonibba Test Range where the capsules land - a recovery zone in the South Australian desert that has quietly become the busiest commercial return address in space.
Varda's stated ambition is to expand the economic bounds of humankind into space - which is the kind of sentence every space company prints. What makes Varda's version credible is the narrowness of the wedge. It is not building space hotels or asteroid mines. It is building a freight service for high-value materials: pharmaceuticals first, then whatever else turns out to be worth more when made in microgravity. Fiber optics. Specialty crystals. Things nobody has tried yet because the shipping was impossible.
The company holds the FAA's first-ever Part 450 reentry license - the regulatory equivalent of a learner's permit for deliberately dropping a spacecraft onto the planet. Boring paperwork, except it is the kind of boring that competitors do not have.
If Varda is right, the interesting question stops being "can you manufacture in space?" and becomes "what is worth manufacturing there?" That is a much better question to have. It implies the infrastructure works and the only thing left to figure out is the catalog. Pharmaceutical companies are already running formulations they cannot replicate on the ground. Defense customers are buying reentry data they cannot get any other way.
So return to the outback. The W-6 is down, the parachute is settling into the red dirt, and a recovery team is walking out to collect a payload that was, until very recently, in space. The remarkable thing is how unremarkable everyone is acting. No countdown drama, no champagne - just another capsule, another batch, another Tuesday. Varda set out to make space manufacturing boring. The fact that it is starting to look routine is the most ambitious thing about it.